PSP stands for progressive supranuclear palsy, a rare neurodegenerative tauopathy causing gait instability, eye movement impairment, and progressive motor and cognitive decline.
Researchers at the University of Toronto have discovered that progressive supranuclear palsy has distinct molecular subtypes based on tau protein distribution, opening pathways for precision medicine approaches to treat this fatal neurodegenerative disease.
NeuraLight will present a neuroprogression biomarker that outperforms the current gold standard for tracking Parkinson's disease progression at the AD/PD 2026 conference in Copenhagen beginning March 17.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07429019 |
Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind Trial |
NOT_YET_RECRUITING | NA |
| NCT07316413 |
Repetitive Transcranial Magnetic Stimulation in Frontotemporal Lobar Degeneration |
RECRUITING | NA |
| NCT07240805 |
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies |
NOT_YET_RECRUITING | |
| NCT06647641 |
The CurePSP Genetics Program |
RECRUITING | |
| NCT06122662 |
AMX0035 and Progressive Supranuclear Palsy |
COMPLETED | PHASE2/PHASE3 |
| NCT05956834 |
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes |
ACTIVE_NOT_RECRUITING | |
| NCT05792332 |
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study) |
ACTIVE_NOT_RECRUITING | NA |
| NCT04680130 |
Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders |
ENROLLING_BY_INVITATION |
